Premium
ALLERGY DIAGNOSIS
Author(s) -
Heger,
A. Globisch,
K. Rasche,
A. Gillissen,
A. Gebler,
G. Schultze-Werninghaus,
A.,
J. Wever
Publication year - 1997
Publication title -
allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.363
H-Index - 173
eISSN - 1398-9995
pISSN - 0105-4538
DOI - 10.1111/j.1398-9995.1997.tb04849.x
Subject(s) - citation , computer science , medicine , library science
It is believed that venom immunotherapy (VIT) acts by inducing specific blocking IgG antibody. However, this protective response is poorly reflected by the measurement of IgG levels. Therefore, in the present study, antibody specificity rather than antibody titers was evaluated in 17 wasp allergic patients before and during rush VIT ( 15 days and 6 months) and in 17 patients treated for at least two years, in a competitive ELISA using the streptavidin biotin technology. The capacity of sera to prevent venom antigen binding of pooled IgG from allergic patients changed rapidly with mean percentage inhibitions falling from 87 f 11 before starting VIT to 45 f 13 and 42 f 7 after 15 days and 6 months of treatment respectively @4lo.0Ol by one way ANOVA), while IgG titers are only slightly increased. The capacity of sera to prevent venom antigen binding of pooled IgG from VIT patients changed also rapidly with mean percentage inhibitions increasing from 49 i 13 before starting VIT to 76 + 11 and 73 + 13 after 15 days and 6 months of treatment respectively (p